Helicos Cuts Q3 Net Loss by Almost 40 Percent; Rules out Potential Sale of Company | GenomeWeb

NEW YORK (GenomeWeb News) – Helicos Biosciences said yesterday that it has for the time being ruled out a potential sale of the company in light of expected revenues through the first quarter of 2010.

In September, Helicos announced that it had hired investment bank Thomas Weisel Partners "to assist the company with its evaluation and execution of strategic alternatives" such as financings, joint ventures, or partnerships.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.